Compare KZIA & EML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KZIA | EML |
|---|---|---|
| Founded | 1994 | 1858 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.8M | 119.2M |
| IPO Year | 2002 | 1995 |
| Metric | KZIA | EML |
|---|---|---|
| Price | $9.98 | $22.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.67 | N/A |
| AVG Volume (30 Days) | ★ 153.1K | 11.2K |
| Earning Date | 11-07-2025 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.02% |
| EPS Growth | N/A | ★ 185.40 |
| EPS | N/A | ★ 1.17 |
| Revenue | N/A | ★ $248,970,345.00 |
| Revenue This Year | N/A | $19.05 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $18.65 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.86 | $17.61 |
| 52 Week High | $17.40 | $26.76 |
| Indicator | KZIA | EML |
|---|---|---|
| Relative Strength Index (RSI) | 68.55 | 70.22 |
| Support Level | $5.74 | $21.76 |
| Resistance Level | $10.92 | $24.15 |
| Average True Range (ATR) | 0.96 | 0.58 |
| MACD | 0.22 | 0.14 |
| Stochastic Oscillator | 76.10 | 100.00 |
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.